Moderna upgraded by BofA Securities
Stocks in this Quantisnow insightHealth Care
Historical context for MRNA
Across the 28 sessions after earlier MRNA headlines, the stock closed higher 14 times and lower 14 times, with a median move of 3.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | MRNA | SPY |
|---|---|---|---|
| Aug 19, 2026 | Moderna upgraded by William Blair | +177.0% | +0.2% |
| Aug 6, 2026 | Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA | -4.3% | -0.2% |
| Aug 4, 2026 | Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus | +3.4% | +1.8% |
| Jul 31, 2026 | Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates | -5.4% | +0.7% |
| Jul 16, 2026 | Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors | -7.5% | -0.5% |
| Jul 9, 2026 | Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026 | +3.7% | +0.8% |
Quantisnow market dataNASDAQ
MRNA
Moderna Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2018
Get push alerts for MRNA
Full MRNA profile on Quantisnow Follow MRNA and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time